APA (7th ed.) Citation

Brannagan, T. H., Wang, A. K., Coelho, T., Waddington Cruz, M., Polydefkis, M. J., Dyck, P. J., . . . Gorevic, P. (2020). Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: A 2‐year update from the open‐label extension of the NEURO‐TTR trial. European Journal of Neurology, 27(8), 1374. https://doi.org/10.1111/ene.14285

Chicago Style (17th ed.) Citation

Brannagan, T. H., et al. "Early Data on Long‐term Efficacy and Safety of Inotersen in Patients with Hereditary Transthyretin Amyloidosis: A 2‐year Update from the Open‐label Extension of the NEURO‐TTR Trial." European Journal of Neurology 27, no. 8 (2020): 1374. https://doi.org/10.1111/ene.14285.

MLA (9th ed.) Citation

Brannagan, T. H., et al. "Early Data on Long‐term Efficacy and Safety of Inotersen in Patients with Hereditary Transthyretin Amyloidosis: A 2‐year Update from the Open‐label Extension of the NEURO‐TTR Trial." European Journal of Neurology, vol. 27, no. 8, 2020, p. 1374, https://doi.org/10.1111/ene.14285.